← Back to Search

18-F FTC 146 for Osteosarcoma

Phase 2
Waitlist Available
Led By Kristen N Ganjoo
Research Sponsored by Davidzon, Guido, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test a new imaging agent to help doctors better understand how a patient's osteosarcoma is responding to treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Detection of Tumor Necrosis Post-chemotherapy
Secondary outcome measures
Maximum Standardized Uptake Value (SUVmax)
Use of Patient Reported Outcomes Measurement Information System (PROMIS) to Assess Treatment Effect

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18-F-FTC 146 PET/CTExperimental Treatment1 Intervention
For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).

Find a Location

Who is running the clinical trial?

Davidzon, Guido, M.D.Lead Sponsor
2 Previous Clinical Trials
70 Total Patients Enrolled
Stanford UniversityLead Sponsor
2,373 Previous Clinical Trials
17,327,961 Total Patients Enrolled
3 Trials studying Osteosarcoma
228 Patients Enrolled for Osteosarcoma
Kristen N GanjooPrincipal InvestigatorStanford Universiy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for interested parties to participate in this experiment?

"Based on the information given at clinicaltrials.gov, this research is not currently open for enrolment. Initially presented on January 28th 2021 with an update being made in September 10 2022, no further progress has been reported as of now. However, there are 112 other studies that have begun to recruit patients already."

Answered by AI

Has 18-F FTC 146 been authorized by the Food and Drug Administration?

"Taking into account the limited research that has been conducted, our team at Power gave an estimate of 2 for 18-F FTC 146's safety profile due to this being a Phase 2 trial without evidence supporting efficacy."

Answered by AI
~0 spots leftby Mar 2025